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still missing real ones. MLR is necessary, but, as in our
report, should be interpreted conservatively, alongside other
forms of reasoning.
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To the Editor: Liu et al. constructed a transgenic mouse
(TM) model overexpressing CYP4F2.1 They found enhanced
20-hydroxyeicosatetraenoic acid (HETE) production and
elevated blood pressure in TM and a positive correlation of
blood pressure with urinary 20-HETE levels, suggesting that
these findings are directly transferable to humans. We feel
that this passage is not so straightforward. 20-HETE has both
pro- and antihypertensive properties, depending on the site
of action: vasculature vs kidney tubuli, a finding that marks
the difference also in animal models, in which 20-HETE is
either prohypertensive (spontaneously hypertensive rats) or
antihypertensive (Dahl salt-sensitive rats). In humans,
CYP4F2 has maximal expression at the renal tubular level,
suggesting a major action of CYP4F2 as a natriuretic
substance. Other studies, in which 20-HETE was measured
using gas chromatography–mass spectrometry techniques,
showed a prevalently antihypertensive role of human 20-
HETE: Laffer2 found that the altered response of 20-HETE is
associated with salt-sensitive hypertension, and our group3
found decreased levels of urinary 20-HETE in patients with
hypertension compared with matched controls.
Moreover, V433M polymorphism, which was cited by the
authors in support of their hypothesis, decreases the activity
of the enzyme in vitro,4 suggesting that a prohypertensive
action can be hypothesized only if it acts at tubular level.
Indeed, this variant was associated with prevalence of hyper-
tension and incidence of stroke in a large population,5 even
though this was found only in males, suggesting a possible
role of testosterone in its regulation, as indicated also by Liu.
Therefore, extrapolation of the findings from the TM model
to humans should be done cautiously. Nevertheless, these
results encourage active research on the effect of eicosanoids
derived by CYP450 in hypertension.
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Our colleagues recently established a novel CYP4F2
transgenic (TG) mouse model that showed increased
20-hydroxyeicosatetraenoic acid (HETE) production and
elevated blood pressure.1 We are thankful to Dr Fava for
his interest and opinion.2 20-HETE, a vasoconstrictor and
a sodium-reabsorption inhibitor, has both prohypertensive
and antihypertensive properties. Reports on the role of
20-HETE in blood pressure regulation remained diverse
both in population association studies, with positive
correlation in some studies3,4 but not in others, and in
rodent models, with a prohypertensive effect in sponta-
neously hypertensive rats but antihypertensive action in
Dahl salt-sensitive rats. These discrepancies indeed
prompted us to construct a CYP4F2 TG model to evaluate
the overall effect of 20-HETE in vivo.
TG mice expressing CYP4F2 at renal tubules and other
extrarenal tissues developed hypertension on increased
20-HETE production, suggesting that a prohypertensive
role of 20-HETE was dominant. As for the antihypertensive
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